Ken Drazan, ArsenalBio CEO

Ar­se­nal­Bio lands $70M cash deal with can­cer gi­ant Genen­tech to de­vel­op cell ther­a­py

San Fran­cis­co-based Ar­se­nal­Bio’s de­sign­er T cells pro­gram is at­tract­ing the at­ten­tion of some big play­ers.

Af­ter clos­ing a deal and grab­bing $70 mil­lion in cash from Bris­tol My­ers Squibb last year, the com­pa­ny is back in the news with a brand new deal, this time with Genen­tech.

Ar­se­nal­Bio will re­ceive $70 mil­lion up­front from Genen­tech along with re­search sup­port, the com­pa­nies an­nounced Tues­day. Un­der the col­lab­o­ra­tion, both com­pa­nies will share re­search ideas and de­vel­op tar­get­ed T cells for sol­id tu­mors.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.